Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

BMC Cancer

Research Article

Haruka Okabe¹  Masako Shomura²  Tatehiro Kagawa³  Koichi Shiraishi³  Shunji Hirose³  Yoshitaka Arase³  Kota Tsuruya³  Tetsuya Mine³  Sachiko Takahira⁴ 

[1] Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa, Japan;Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa, Japan;143 Shimokasuya, 259-1193, Isehara-city, Kanagawa, Japan;Division of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan;University of Nagasaki Department of Nursing, Nagasaki, Nagasaki, Japan;

关键词: Advanced hepatocellular carcinoma;    Sorafenib;    Health-related quality of life;    Clinical course;    Prognostic marker;   

DOI  :  10.1186/s12885-016-2908-7

 received in 2016-04-27, accepted in 2016-10-28,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThis study aimed to identify the health-related quality of life (HRQOL) domains associated with prognosis by assessing longitudinal alterations in HRQOL in patients with advanced hepatocellular carcinoma receiving sorafenib.MethodsWe prospectively assessed HRQOL by administering the SF-36 questionnaire 3-monthly to consecutive patients with advanced hepatocellular carcinoma receiving sorafenib. We evaluated the impact of HRQOL on their overall survival and duration of treatment with sorafenib using Cox's proportional hazards model.ResultsThere were 54 participants: 42 (78 %) were male, the median age was 71 years, 24 (44 %) had hepatitis C virus infection, 33 (61 %) had Child-Pugh scores of 5, and 30 (56 %) had TNM stage IV hepatocellular carcinoma. The median overall survival and treatment duration were 9 and 5 months, respectively, and 40 patients (74 %) died. Thirteen patients receiving sorafenib over a 1-year period maintained all domain scores >40, without a significant decline during the treatment period. In contrast, physical functioning, physical role, and vitality scores declined continuously and significantly in the year before death (in the 40 patients who died). Previous curative treatment and physical functioning scores ≥40 at baseline were significantly associated with longer overall survival by multivariate analysis. Social functioning scores ≥40, absence of vascular invasion, and lower DCP value were significant predictors of longer treatment duration.ConclusionsHRQOL was not significantly impaired in those patients who were able to complete a 1-year course of sorafenib treatment. Baseline physical functioning scores ≥40 and social functioning scores ≥40 were significantly associated with longer overall survival and longer treatment duration, respectively. Thus, HRQOL could be a valuable marker to predict the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib.

【 授权许可】

CC BY   
© The Author(s). 2016